摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 4-(((2-chloropyrimidin-5-yl)oxy)methyl)piperidine-1-carboxylate | 1314391-51-9

中文名称
——
中文别名
——
英文名称
tert-butyl 4-(((2-chloropyrimidin-5-yl)oxy)methyl)piperidine-1-carboxylate
英文别名
Tert-butyl 4-([(2-chloropyrimidin-5-YL)oxy]methyl)piperidine-1-carboxylate;tert-butyl 4-[(2-chloropyrimidin-5-yl)oxymethyl]piperidine-1-carboxylate
tert-butyl 4-(((2-chloropyrimidin-5-yl)oxy)methyl)piperidine-1-carboxylate化学式
CAS
1314391-51-9
化学式
C15H22ClN3O3
mdl
——
分子量
327.811
InChiKey
VZWHWTGPQVLTSW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    64.6
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • PIPERIDINE DERIVATIVES FOR GPR119 AGONIST
    申请人:CHONG KUN DANG PHARMACEUTICAL CORP.
    公开号:US20150166480A1
    公开(公告)日:2015-06-18
    The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.
    本发明涉及新型的哌啶衍生物、它们的立体异构体或药用可接受的盐;制备该化合物的方法;以及包含该化合物的药物组合物。根据本发明,具有GPR119激动剂作用的新型哌啶衍生物可用于治疗代谢紊乱,包括糖尿病(尤其是II型)及相关疾病。
  • [EN] PIPERIDINE DERIVATIVES FOR GPR119 AGONIST<br/>[FR] DÉRIVÉS DE PIPÉRIDINE AGONISTES DE GPR119
    申请人:CHONG KUN DANG PHARM CORP
    公开号:WO2013187646A1
    公开(公告)日:2013-12-19
    The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.
    本发明涉及新型哌啶衍生物,其立体异构体或其药学上可接受的盐;制备该化合物的方法;以及包含该化合物的药物组合物。根据本发明,具有GPR119激动剂作用的新型哌啶衍生物可用于治疗代谢性疾病,包括糖尿病(特别是II型)及相关疾病。
  • [EN] COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119<br/>[FR] COMPOSÉS CONTENANT DU BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXYDE OU DU BENZO[D][1,3]OXATHIOLE 3,3-DIOXYDE POLYSUBSTITUÉ, ET LEURS PROCÉDÉS/UTILISATIONS EN TANT QU'AGONISTES DU RÉCEPTEUR 119 COUPLÉ À LA PROTÉINE G
    申请人:PRAMANA PHARMACEUTICALS INC
    公开号:WO2019104418A1
    公开(公告)日:2019-06-06
    There are provided compounds having formula (I), in which: X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 is selected from CH, CF and N; X4 is selected from CH and N; X6, X6' and X6'' are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X7 and X7' are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X7 and X7' together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I)
    提供具有化学式(I)的化合物,其中:X1和X2从O、S、SO和SO2的某些组合中选择;X3从CH、CF和N中选择;X4从CH和N中选择;X6、X6'和X6''从H、卤素以及某些烷基、卤代烷基、烷氧基、羟基烷基和酰胺基中选择;X7和X7'从H、卤素以及某些烷基、卤代烷基、烷氧基、羟基烷基、氨基烷基和酰胺基中选择,或者X7和X7'一起形成环烷基或杂环;A从某些可选择取代的烷氧基、哌嗪基和吡咯烷基中选择。还提供包含这些化合物的组合物,以及与之相关的用途/方法,包括治疗与GPR119失调、2型糖尿病以及相关代谢紊乱相关的疾病和症状。
  • 벤조[d][1,3]옥사티올, 벤조[d][1,3]옥사티올 3-옥사이드 또는 벤조[d][1,3]옥사티올 3,3-디옥사이드를 함유하는 화합물 및 G 단백질 커플링된 수용체 119의 작용제로서 이의 방법/용도
    申请人:PRAMANA PHARMACEUTICALS INC. 프라마나 파마슈티컬스 인크.(520180806346)
    公开号:KR20190015535A
    公开(公告)日:2019-02-13
    본 발명에서는 벤조[d][1,3]옥사티올, 벤조[d][1,3]옥사티올 3-옥사이드, 및 벤조[d][1,3]옥사티올 3,3-디옥사이드를 함유하는 화합물 뿐만 아니라 GPR119 이상조절과 관련된 질환 및 병태, 2형 진성 당뇨병, 및 관련된 대사 장애의 치료를 포함하는 상기 화합물에 관한 관련된 용도/방법이 제공된다.
    本发明提供了一种含有苯并[d][1,3]噻二唑、苯并[d][1,3]噻二唑-3-氧化物和苯并[d][1,3]噻二唑-3,3-二氧化物的化合物,以及与GPR119调节和相关的疾病和病理、2型糖尿病以及相关代谢紊乱的治疗有关的该化合物的相关用途/方法。
  • [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE
    申请人:MERCK SHARP & DOHME
    公开号:WO2011084402A1
    公开(公告)日:2011-07-14
    The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    本发明涉及吡啶并嗪-4(1H)-酮衍生物,用于治疗细胞增殖性疾病,治疗与MET活性相关的疾病,并抑制受体酪氨酸激酶MET。该发明还涉及包含这些化合物的组合物,以及利用它们治疗哺乳动物癌症的方法。
查看更多